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Abstract
Background The number of cardiac rhythm device implanta-
tions has been growing fast due to expanding indications and
ageing of the population. Complications of implantation were
rare in the trials. However, these involved small numbers and
selected patients. Prospective real-life data are necessary to
assess cardiac device implantation procedure-related risks.
Objective To determine the incidence and predictors of lead-
related re-intervention in a Dutch high-volume teaching
hospital.
Methods Data from all patients who underwent cardiac rhythm
device implantation between January 2010 andDecember 2011
were collected in a prospective registry. At least 1 year of
follow-up regarding re-intervention was available for all pa-
tients. Lead-related reasons for re-intervention were categorised
into lead dislodgement, malfunctioning or perforation.
Results One thousand nine hundred twenty-nine devices in-
cluding 3909 leads were implanted. In 595 patients (30.8 %) a
CRT-D/P was implanted. Lead-related re-intervention was
necessary in 86 (4.4 %) patients; it was more common in
younger and male patients, and due to either lead dislodge-
ment (66 %), malfunctioning (20 %) or perforation (18 %).
Coronary sinus lead dislodgement or malfunctioning was
1.4 %. Right atrial dislodgement (1.9 %, p<0.001) or ICD
lead dislodgement (1.8 %, p=0.002) was more common than
right ventricular dislodgement (0.3 %). The incidence of lead
malfunctioning was higher (0.8 %) in ICD leads. An apical
position of the right ventricular lead and lateral wall position
of the right atrial lead were related to cardiac perforation.
Conclusions The incidence of lead-related re-intervention
was comparable with the literature. The majority of re-
interventions were due to lead dislodgements, particularly
with right atrial and ICD leads. Re-intervention due to coro-
nary sinus lead dislodgement was rare.
Keywords Lead complication . Dislodgement .
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Introduction
The number of cardiac rhythm device implantations, includ-
ing implantable cardioverter defibrillator (ICD) and cardiac
resynchronisation therapy (CRT) devices, has increased fast in
the past decade due to expanding indications and ageing of the
population. Although the benefits of these devices were dem-
onstrated in randomised controlled trials, this concerned se-
lected patients and real-life data are necessary to assess cardiac
device implantation-related risks. Several prospective and
retrospective studies reported both short- and long-term com-
plications related to device implantation and pacing system
upgrade. However, the majority of these reports are derived
from randomised clinical trials which reflect selected patients
and circumstances [1] whereas other studies concern relatively
old reports, also including leads with passive fixation, which
are nowadays less commonly used [2–8].
The objective of this prospective registry study was to
assess the real-life incidence of lead dislodgement,
malfunctioning or perforation during the first year following
implantation in a Dutch high-volume teaching hospital.
Methods
Data on all patients who underwent procedures of de novo
cardiac rhythm device implantations and pacing system up-
grades in our hospital between January 2010 and December
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2011 were prospectively collected. The indications for the
implantation of pacemakers, ICD and CRT devices were
based on contemporary guidelines [9, 10]. The procedures
were performed by seven operators including two cardiac
electrophysiology fellows under direct supervision of an at-
tending cardiac electrophysiologist, in cardiac catheterisation
laboratories equipped according to the guidelines of the
European Society of Cardiology (9). The leads and devices
were implanted according to the manufacturers’ recommen-
dations. The baseline characteristics of patients including age,
gender, left ventricular ejection fraction (LVEF), presence of
conduction disorders and functional New York Heart
Association (NYHA) class were recorded in the prospective
database. To identify the lead-related complications the data-
base was searched for re-intervention procedures during the
first year following the implantation. In all lead-related re-
intervention cases, data on the clinical manifestation and
course, results on chest X-ray, echocardiography and technical
data on lead performance were collected.
Definition of complications
Lead dislodgement was defined if there was documentation
of a change in the lead tip position on chest X-ray and changes
in electrical lead parameters (rise in impedance, loss of sens-
ing and pacing).
Lead electrical malfunctioning was defined if lead im-
pedance, electrogram amplitude or threshold had changed
abruptly necessitating surgical revision without clear changes
in the position of the lead on chest X-ray.
Lead perforation was defined in case of high suspicion of
cardiac perforation, e.g. an acute stabbing chest pain or dys-
pnoea, significant changes in electrical lead parameters and a
significant amount of pericardial effusion requiring
pericardiocentesis with or without extracardiac lead location
on X-ray.
Screw perforation was defined if there were pericarditis-
like symptoms without clear changes in electrical lead param-
eters and absence of a significant amount of pericardial
effusion.
Statistical analysis
Statistical analysis was performed using SPSS statistical soft-
ware (IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, Version 20.0. Armonk, NY: IBM Corp).
Continuous variables are expressed as mean ± SD and P value
was calculated by using the ANOVA test. Categorical vari-
ables were presented as numbers and percentages and signif-
icance of differences were analysed using the χ2 test or
Fisher’s exact test. The denoted p values were two-sided and
p<0.05 was considered significant.
Results
During a period of 2 years, 1929 cardiac rhythm devices and
3909 leads were implanted in 1929 consecutive patients with
commonly accepted indications for either pacemaker, ICD or
CRT device implantation. The baseline characteristics of pa-
tients and type of device implantation are summarised in
Table 1. Patients with pacemaker indications were older than
ICD patients and 66 % of patients with cardiac rhythm device
implantations were male. All leads except the coronary sinus
leads were actively fixed. Device and lead manufacturers
included Medtronic, St. Jude Medical, Biotronik, Sorin
Group and Boston Scientific. Of all implanted devices, 1148
(60 %) were ICDs and 1148 (29 %) of all implanted leads
were ICD leads. Details regarding implanted devices and
leads are summarised in Figs. 1 and 2.
Thirty-one (1.5 %) patients were re-admitted because of
cardiac device infection, and all had explantation of their
device. One (3.2 %) patient died within 30 days of
hospitalisation. Positive cultures were present in 27/31
(87 %) cases. These consisted predominantly of micro-
organisms that are part of the skin flora (84 %).
Re-intervention
A total of 90 (2.3 % of the leads) lead-related complications
occurred in 86 (4.4 %) patients for which re-intervention was
needed. The cause of re-intervention was mainly lead dis-
lodgement (66 %), followed by malfunctioning (20 %) and
perforation (18 %). Re-intervention was more common in
men compared with women (70 % vs 30 % p=0.001).
Younger patients more often had re-intervention (mean age
65±13 vs 70±13 years, p=0.001).
Lead dislodgement or malfunction and time of occurrence
A total of 3909 leads were implanted. During the first year of
follow-up a total of 74 (1.9 %) lead dislodgements or
malfunctions occurred in 71 (3.7 %) patients: 57 (1.4 %)
dislodgements and 17 (0.5 %) malfunctions. Regarding lead
dislodgement, the right atrial (RA) lead (1.9 %) showed the
most frequent lead dislodgement compared with the right
ventricular (RV) pacemaker lead (0.3 %) or ICD lead
(1.8 %) (p=0.0007 and p=0.002), Table 2. Only 6 (1 %)
coronary sinus (CS) leads dislocated requiring re-
intervention. Regarding lead malfunction, the ICD lead
(0.8 %) showed the most frequent lead malfunction compared
with the RA lead (0.1 %) (p=0.002), Table 2. The timing of
occurrence of lead dislodgement/malfunction is summarised
in Fig. 3. The majority of RA and RV lead dislodgements
occurred before discharge whereas the majority of RA and RV
lead malfunction occurred after the 2nd month following
implantation. All CS lead dislodgements or malfunctions
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occurred after the 2nd month following implantation. In al-
most 1/3 of the cases the sleeves on the leads were not fixed
adequately and in 2/3 of the cases the cause of dislodgement
was unclear. All re-do interventions were conducted without
further complications.
Lead dislodgement per device type
In this study 595 CRT-D/P devices were implanted. In the
CRT-D group, significantly more lead dislodgments or
malfunctions were observed compared with the single-
chamber pacemaker (30 versus 3, p=0.006). The risk of any
lead dislodgement or malfunctioning was higher in CRT-D
(5 %, p=0.006) and dual-chamber ICD (5.8 %, p=0.002) as
compared with single-chamber pacemaker (1.2 %). Numbers
of lead dislodgements per type of device are summarised in
Table 3.
Lead or screw perforation
During follow-up, 16 leads (0.4 % of the leads) showed
screw/lead perforation in 15 (0.8 %) patients. They were
re-admitted to the hospital with pericarditis-like symp-
toms suspected for cardiac perforation. The clinical pre-
sentation of all suspected cardiac perforations was sub-
acute (±21 days after implantation). Fourteen patients
were implanted with single- or dual-chamber pacemaker
and one patient with single-chamber ICD. The majority of
these patients were re-admitted after the first week of
implantation (Fig. 3). Ten patients were re-admitted with
pericarditis-like symptoms with a slight amount (<0.5 cm)
of pericardial effusion on the echocardiogram. In these
patients only repositioning of the lead was sufficient
without need for pericardiocentesis. The other five pa-
tients were re-admitted with symptoms of cardiac
tamponade and a significant amount of pericardial effu-
sion (>2 cm, with >25 % respiratory mitral flow variation)
on the echocardiogram, suspect for lead perforation with-
out obvious extracardiac location of a lead on chest X-ray.
In these 5 (0.26 %) patients, with dual-chamber pace-
makers, pericardiocentesis was necessary and performed.
In all cases a repositioning or implantation of a new lead
was performed without further complications and without
the need for thoracic surgical intervention. In all patients,
the pericarditis-like symptoms disappeared after reposi-
tioning of the suspected lead. From the 16 (0.4 %)
lead/screw perforations, 7 were RA leads, 8 were RV
pacemaker leads and 1 was an active fixation ICD lead.
RV pacemaker leads caused significantly more lead/screw
perforation compared with ICD leads (p=0.02), Table 3.
All RV leads causing perforations were located in RV
apex region and four out seven RA leads which caused
perforation were located in the lateral wall of the right
atrium.
Lead or screw perforation per type of device
Most lead/screw perforations (12 cases) occurred in dual-
chamber pacemakers compared with single-chamber pace-
makers (2 cases) or single-chamber ICD (1 case) (p=0.02).
There were no lead/screw perforations in dual-chamber ICD
or CRT-D/P devices. The rate for lead/screw perforation in
dual-chamber pacemakers was 3%,whereas this did not occur
in CRT-D/P patients. Numbers of leads/screw perforations per
type of device are summarised in Table 3.









CRT-P N=91 CRT-D N=504 P-value
Age (year) 78±11 74±11 61±13 65±11 72±12 69±9 P<0.001
Male (%) 55 55 72.5 77 65 76 P<0.001
LVEF (%) – – 30±9 31±12 40±13 26±11 P<0.001
NYHA class – – 2.1±0.5 2.2±0.6 2.3±0.9 2.4±1 P=0.1
QRS duration (ms) – – 112±33 112±40 143±60 161±59 P<0.001
P value is calculated by using ANOVA test
CRT cardiac resynchronisation therapy, ICD implantable cardioverter defibrillator, LVEF left ventricular ejection fraction, NYHA classNew York Heart
Association functional class, PM pacemaker
Fig. 1 A total of 1929 cardiac rhythm devices implanted
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Discussion
In this prospective device complication registry of 1929 pa-
tients, 4.4 % of patients suffered from a lead dislodgement,
malfunctioning or perforation during the first year following the
implantation. The overall rate of lead dislodgement,
malfunctioning or perforation requiring re-intervention was
low (2.3 % of 3909 leads) in our study. RA and ICD leads
were the leads with the highest risk (1.9 %) of dislodgement
compared with RV pacemaker and coronary sinus leads. The
rate of leadmalfunctioning was higher in ICD leads. The rate of
coronary sinus lead dislodgement or malfunction within the
first year following the implantation was very low in this study
(1.4 %). Dual-chamber ICD implantation was the procedure
with the highest risk of lead dislodgement and DDD pacemaker
implantation with the highest risk of lead perforation. The
overall lead dislodgement rate in our hospital is low and com-
parable (1.5–3.3 %) with published studies [2, 6, 10–14]. The
CRT trials [2, 13–15] reported any lead dislodgement rate
varying from 2.9 to 10.6 %. In our hospital the rate of any lead
dislodgement in CRT-D/P devices was 5%. In CRT devices the
lead failure rate exceeds the rate of lead failure in one- or two-
chamber devices. This is comprehensible since more leads are
implanted per device. The low rate of any lead dislodgements
of 5 % in our group could be explained by a low rate of
coronary sinus lead dislodgements. The rate of coronary sinus
lead dislodgement in the present study is low (1.4 %) compared
with previous reports (4.0–8.4 %) [16, 17]. There are several
possible explanations. The coronary sinus leads are today more
diverse with different shapes and thicknesses. These properties
enable the operators to choose the lead which fits best in the
side branches of the coronary sinus. Also the use of inner
catheters and selective shackling of the side branches makes it
easier to advance the lead inside the vessel and to achieve a
stable position. A possible other explanation is the experience
of the operator. Almost all coronary sinus leads were implanted
by three very experienced operators in our hospital.
Furthermore, since coronary sinus leads of all different manu-
factures are available in our hospital during the implantation,
and there is no preferred manufacturer assigned to a case, the
most suitable lead can be chosen to be implanted according to
the anatomy, enhancing the success rate.We tried to identify the
causes of lead dislodgments. In almost 1/3 of the cases the
sleeves on the leads were not fixed adequately and in 2/3 of the
cases the cause of dislodgement was unclear. This means that in
1/3 of the cases a lead dislocation could be prevented by
adequate fixation. In the present study all lead/screw perfora-
tions were subacute and the incidencewas very low (0.8%) and
comparable with (0.6–5.2 %) the published reports [1, 5, 7].
DDD pacemakers caused the most perforations (12 cases) and
the majority of perforated leads were RV leads. There are
several possible explanations. 1) All perforated RV leads were
located in the RV apex which is the thinnest part of the right
ventricle. In our routine practice we try to avoid the apex if
possible and position the RV leads in a septal region if sufficient
sensing and pacing values are present. 2) The relatively small
size of the lead, 6–7 French, which more easily perforates the
apex compared with the thick high-voltage ICD (8–9 French)
lead and, according to Laplace’s law (p = F/A; pressure is the
Fig. 2 A total of 3909 leads implanted
Table 2 Lead dislodgement, malfunctioning and perforation




Atrial leads 1442 28 (1.9) 2 (0.1) 5 (0.3) 2 (0.1)
RV pacemaker leads 724 2 (0.3) 4 (0.5) 1 (0.1) 7 (0.9)
ICD leads 1148 21 (1.8) 9 (0.8) – 1 (0.08)
Coronary sinus leads 595 6 (1)£ 2 (0.3) – –
Total 3909 57 (1.5) 17 (0.4) 6 (0.15) 10 (0.25)
P value is calculated by using Fisher exact test
ICD implantable cardioverter defibrillator, RV right ventricular
P=0.0007 compared with RV pacemaker lead as reference
p=0.002 compared with RV pacemaker lead as reference
£ p=0.15 compared with RV pacemaker lead as reference
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amount of force acting on a unit area), it is easy to understand
that when the surface area is smaller, then the pressure will be
higher on that surface area. 3) Also the experience of operators
plays an important role. In our teaching hospital most pace-
makers were implanted by less experienced operators, cardiol-
ogists in training, and ICDs and CRTs by very experienced
operators. The majority of perforated RA leads were located in
the lateral wall, which is not the preferred site, due to unstable
position or insufficient electrical signals and therefore the op-
erator was forced to choose for this site.
Strength and limitations of study
This study demonstrates the real-world common daily practice
by implanting a large number of devices in a teaching hospital.
Meticulous longitudinal follow-up was performed, with docu-
mentation of complications in all patients. This study also has
certain limitations. We identified the re-intervention due to lead-
related complication when the patients were returned to cardiac
catheterisation laboratories within first year of implantation.
Patients with lead-related complications who did not return for
re-intervention based on the opinion of their cardiologists could
be missed in our registry. Furthermore, the follow-up period in
the present study is no longer than 1 year. However, most lead
dislocations and perforations are expected to occur within 1 year
[1, 7, 11]. This is also supported by our own data. To obtain
reliable information about the rate of complications, we used
predefined definitions of complications. We focused on lead
dislodgement, malfunctioning and perforations. Other device-
related complications, including infection, were beyond the
scope of this study. Our analysis also did not evaluate mortality
and duration of hospitalisation in the study population.
Conclusions
In this large observational study, lead related re-intervention
was necessary in 4.4 % of patients, more common in younger
and male patients, and due to either lead dislodgement (66 %),
malfunctioning (20 %) or perforation (18 %). With a total of
3909 leads implanted, the incidence of lead dislodgement,
Fig. 3 Timing of either lead dislodgement, malfunctioning or perfora-
tion. The majority of lead dislodgements occurred before discharge and
all perforations occurred after the 2nd month of implantation. LD 1 lead
dislodgement before discharge, LM 1 lead malfunctioning before dis-
charge, LP 1 lead perforation before discharge, LD 2 lead dislodgement
between discharge and 2 months, LM 2 lead malfunctioning between
discharge and 2 months, LP 2 lead perforation between discharge and
2 months, LD 3 lead dislodgement between 2 months and 1 year, LM 3
lead malfunctioning between 2 months and 1 year, LP 3 lead perforation
between 2 months and 1 year
Table 3 Lead dislodgement and type of device
Type of device Number of lead
dislodgement or
malfunction
Risk of any leads lead
dislodgement or malfunction
Number of lead/screw perforation
with or without pericardiocentesis
Risk of lead/screw perforation
with or without pericardiocentesis
Single chamber PM 3 1.2 % 3* 0.8 %
Dual chamber PM 10 2.3 % 12# 3.0 %
Single chamber ICD 10† 3.5 % 1 0.3 %
Dual chamber ICD 21 5.8 % 0 0 %
CRT-D/P 30£ 5.0 % 0 0 %
CRT cardiac resynchronisation therapy, ICD implantable cardioverter defibrillator, PM pacemaker
† p=0.09 compared with single chamber pacemaker as reference
p=0.002 compared with single chamber pacemaker as reference
£ p=0.006 compared with single chamber pacemaker as reference
* p=0.35 compared with single chamber ICD as reference
# p=0.02 compared with single chamber ICD as reference
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malfunction or perforation was low (2.3 %). Right atrial and
ICD leads caused more dislodgement compared with RV
pacemaker leads. Lead perforation was more common with
RV leads, especially when placed in the apex. In the patients
with lead perforation, pericardiocentesis was only necessary
in 1/3. With 1929 devices implanted, more lead complications
were observed in dual-chamber ICD and CRT-D/P.
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